WE SEEK TO DELIVER INNOVATION
Averitas Pharma, a leader in the US for holistic pain management, was formed in 2018 as the US commercial subsidiary of The Grünenthal Group, a global leader in research and development of therapeutics for pain, gout, and inflammation. The first innovation from Averitas Pharma in the US is QUTENZA, which is a result of acquisitions in 2016 and 2018. These acquisitions give Grünenthal global commercial rights to QUTENZA and provide Averitas with its first FDA-approved product for distribution. QUTENZA is currently marketed and distributed by Averitas Pharma.

Find out more about The QUTENZA Difference through the resources below or by meeting with our team at a virtual table. We also welcome you to join us for breakfast at one of our Sunrise Sessions or learn more about QUTENZA at our product demonstrations taking place throughout the conference.

Access Averitas Pharma's materials from their exhibit and Sponsored Sessions at the 2021 Virtual Annual Assembly.